Seroquel Poised To Take Market Lead Within Months – AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca expects Seroquel to surpass Johnson & Johnson's Risperdal in terms of prescription share within the antipsychotic market by the end of the year